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Summary
Background: Due to increasing use of new oral anticoagu-
lants (NOACs), clinicians are faced more and more frequent-
ly with clinical issues related to these drugs. Objective: The 
objective of this publication is to make practical suggestions 
for the perioperative management of NOACs as well as for 
their handling in overdoses and bleedings. Recommenda-
tions: In elective surgery and creatinine clearance ≥ 50 ml/
min, a NOAC should be discontinued 24–36 h before the in-
tervention, and even earlier in case of reduced kidney func-
tion. In emergency interventions that cannot be delayed, the 
management is dependent on the NOAC plasma levels. With 
levels ≤ 30 ng/ml, surgery can be performed. With levels >30 
ng/ml, reversal agents should be considered. In low bleed-
ing risk surgery, NOACs can be re-started 24 h after the inter-
vention, which is prolonged to 48–72 h after surgery with 
high bleeding risk. In case of NOAC overdose and minor 
bleedings, temporary discontinuation and supportive care 
are usually sufficient to control the situation. In severe or life-
threatening bleedings, nonspecific and specific reversal 
agents should be considered. © 2019 S. Karger AG, Basel
Introduction
New oral anticoagulant (NOAC) agents have been in-
creasingly used in the prevention and treatment of throm-
boembolic events in the last few years. The four NOACs 
currently available in Europe directly target and inhibit 
either factor Xa (apixaban, edoxaban and rivaroxaban) or 
thrombin (dabigatran).
In addition to having numerous practical advantages 
– simple dosage schemes and no need for laboratory 
monitoring – over previous treatments using vitamin K 
antagonists (VKAs), NOACs are also demonstrating clin-
ical benefits. Meta-analyses and systematic reviews com-
paring NOACs to the VKA warfarin provided evidence 
of NOACs having similar to superior efficacy in prevent-
ing stroke and systemic thromboembolic events in pa-
tients with non-valvular atrial fibrillation (nvAF), while 
significantly reducing the likelihood of major and espe-
cially intracranial bleeding [1–5].
While all four available NOACs are indicated and have 
proven efficacy in patients with nvAF as well as for treat-
ment and secondary prophylaxis of deep-vein thrombo-
sis and pulmonary embolism [6–12], only three (dabiga-
tran, apixaban, rivaroxaban) have so far been cleared for 
the prevention of thromboembolic events after major 
knee or hip surgery in Europe and the US [13–18]. Only 
two (apixaban, rivaroxaban) are currently available for 
this indication in Switzerland [6, 7, 19] (table 1). 
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Rivaroxaban, in combination with low-dose acetylsal-
icylic acid (ASA), is approved in Europe and the US for 
prevention of major cardiovascular events in patients 
with chronic coronary artery disease (CAD) or periph-
eral arterial disease (PAD) [13, 16].
Due to the widespread use of NOACs, clinicians are 
faced more and more frequently with issues concerning 
the perioperative management of such patients.
The aim of this publication is to provide a practical 
update about NOACs for the perioperative setting. It con-
tains an overview of the pharmacological characteristics 
of the available NOACs and suggestions for procedures 
for the respective perioperative management of elective 
and emergency interventions. Other clinical situations, 
such as overdoses and bleeding under NOACs, will be ad-
dressed as well.
Key Factors for the Preoperative Estimation of 
Bleeding Risk in NOAC Patients
The intra- and postoperative bleeding risk is influ-
enced by the product and application characteristics of 
the NOAC, patient-related factors, and the type of inter-
vention. High bleeding risk means that a patient is at risk 
of losing a large amount of blood or bleeding occurs in a 
critical, closed space with potentially severe consequenc-
es.
NOACs: Approved Indications and Dosages
All NOACs block an activated coagulation factor, ei-
ther FXa (apixaban, edoxaban, rivaroxaban) or FIIa 
(thrombin; dabigatran), thus halting the coagulation cas-
cade and preventing clot formation. Despite the similar 
mode of action, the different NOACs vary in several prac-
tically relevant aspects, such as their approved indica-
tions, pharmacokinetic properties, and dosage schemes. 
In table  1 the approved indications and corresponding 
dosage schemes recommended by Swiss, European and 
US American drug information agencies are listed. How-
ever, for some patients an adaptation of the dosage is ad-
vised, as age, body weight, and renal or liver functions can 
have an influence on the drug’s dynamics [6–9, 20].
Pharmacokinetic Profiles
In order to perform surgery at a time of minimal bleed-
ing risk, the timing of last intake and the pharmacoki-
netic properties of the NOAC used have to be considered, 
some of which are summarized in table 2. Especially the 
time to peak concentration (Tmax/Cmax), the half-life 
(T1/2) and the elimination pathway are important pieces 
of information that should be factored in patient manage-
ment. 
Drug Interactions
NOACs were developed to offer advantageous treat-
ment alternatives to the VKAs [24, 25]. The reduction of 










nvAF 2 × 150 
2 × 110 1
2 × 5 
2 × 2.5 3
1 × 60 
1 × 30 6
1 × 20  
1 × 15 7,8
Therapy DVT/PE 2 × 150 2 2 × 10 for 7 days,
then 2 × 5 
1 × 60 2
1 × 30 6
2 × 15 for 3 weeks, 
then 1 × 20 
Prevention of recurrent DVT/PE 2 × 150 
2 × 110 1
2 × 2.5 1 × 60 1 × 20 
Prevention of TE in major hip or knee surgery – 2 × 2.5 4,5 – 1 × 10 9, 10
Europe (EMA)16
nvAF 2 × 150 2 × 5 1 × 60 1 × 20 
2 × 110 11 2 × 2.5 13 1 × 30 17 1 × 15 7,8
Therapy DVT/PE 2 × 150 
2 × 110 11
2 × 10 for 7 days, 
then 2 × 5 
1 × 60 
1 × 30 17
2 × 15 for 3 weeks, 
then 1 × 20 
Prevention of recurrent DVT/PE 2 × 150 
2 × 110 11
2 × 5  
2 × 2.5 14
1 × 60 
1 × 30 17
1 × 20  
1 × 10 14,18
Prevention of TE in major hip or knee surgery 1 × 110 mg 
first day, 
then 2 × 110 12
2 × 2.5 15 – 1 × 10 10
Prevention of atherothrombotic events after ACS with 
elevated cardiac biomarkers
– – – 2 × 2.5 9, 19
Prevention of atherothrombotic events in CAD or  
symptomatic PAD
– – – 2 × 2.5 9, 20
Table 1 continued on next page
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drug/drug and drug/food interactions are among the 
most relevant advantages of NOACs over VKAs [24, 26]. 
As NOACs are partially eliminated through P-glycopro-
teins (P-gp) transport proteins and cytochrome P450 en-
zymes, there is still a potential of interference with drugs 
that use the same pathways. Such interactions may ulti-
mately lead to over- or under-anticoagulation [27].
Recommendations are mainly based on pharmacoki-
netic studies measuring plasma levels of drugs with the 
same metabolic pathways as NOACs, as only little data is 
available on the bleeding risk of combining NOACs with 
other medications. A new population-based cohort study 
with over 90,000 atrial fibrillation (AF) patients found a 
high risk of major bleeding for NOAC patients who were 
also taking amiodarone and fluconazole, in line with their 
respective pharmacokinetic data. Surprisingly, the higher 
risk of major bleeding was also prevalent for NOAC pa-
tients taking rifampicin and phenytoin, which, according 
to their pharmacokinetic profiles, lead to lower NOAC 











nvAF 2 × 150 21 2 × 5 1 × 60 27 1 × 20 29
2 × 75 22,23 2 × 2.5 25 1 × 30 28 1 × 15 30
Therapy DVT/PE 2 × 150 21 2 × 10 for 7 days, 
then 2 × 5 
1 × 60  
1 × 30 28
2 × 15 for 3 weeks, 
then 1 × 20 
Prevention of recurrent DVT/PE 2 × 150 21 2 × 5  
2 × 2.5 14
no mention 1 × 20  
1 × 10 14,18
Prevention of TE in major hip or knee surgery 1 × 110 mg first day, 
then 1 × 220 24
2 × 2.5 26 – 1 × 10 26
Risk reduction of major CV events (CV death, MI, 
and stroke) in chronic CAD or PAD
– – – 2 × 2.5 9,20
nvAF = Non-valvular atrial fibrillation; DVT = deep-vein thrombosis; PE = pulmonary embolism; TE = thromboembolism; EMA = 
European Medicines Agency; ACS = acute coronary syndrome; CAD = coronary artery disease; PAD = peripheral arterial disease; FDA 
= Food and Drug Administration; CV = cardiovascular.
1CrCl 30–50 ml/min, or >80 years.
2After initial treatment with UFH or LMWH for 5 days.
3Patients with at least two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl (133 µmol/l).
4Duration of treatment: hip replacement 32–38 days, knee replacement 10–14 days.
5Indication: elective hip and knee replacement.
6CrCl 15–50 ml/min, body weight ≤ 60 kg, or concomitant therapy with potent P-gp inhibitors.
7CrCl 30–49 ml/min.
8Rivaroxaban is also admitted for CrCl 15–29 ml/min; careful application required, no dosage recommendation.
9Can be taken independent of food, whereas 15 mg and 20 mg should be taken with food to assure bioavailability.
10Duration of treatment: major hip surgery 5 weeks, major knee surgery 2 weeks.
11Age ≥ 80 years, or patients receiving concomitant verapamil.
12Duration of treatment: hip replacement 28–35 days, knee replacement 10 days.
13Patients with at least two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl (133 µmol/l).
14After at least 6 months of treatment for DVT or PE.
15 Duration of treatment: hip replacement 32–38 days, knee replacement 10–14 days.
16EMA advises that ‘edoxaban should only be used in patients with nvAF and high creatinine clearance after careful evaluation of the 
individual thromboembolic and bleeding risk’.
17Patients with one or more of the following clinical factors: CrCl 15–50 ml/min, body weight ≤ 60 kg, concomitant use of P-gp in-
hibitors.
18Patients with high risk of recurrent DVT/PE consider administering 1 × 20 mg/day.
19In combination with acetylsalicylic acid (1 × 75–100 mg/day) or acetylsalicylic acid (1 × 75–100 mg/day) in addition to either clopi-
dogrel (1 × 75 mg/day) or a standard dose of ticlopidine (once daily).
20In combination with acetylsalicylic acid (1 × 75–100 mg/day). 
21CrCl>30 ml/min.
22CrCl between 15 and 30 ml/min.
23If given with P-gp inhibitors dronedarone or systemic ketoconazole.
24Duration of treatment: hip replacement 28–35 days.
25Patients with at least two of the following criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dl.
26Duration of treatment: hip replacement 35 days, knee replacement 12 days.
27FDA provides a boxed warning that “edoxaban should not be used in patients with CrCl > 95 ml/min.
28For patients with CrCl 15–50 ml/min.
29If CrCl > 50 ml/min.
30If CrCl 15–50 ml/min.
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known mechanism. Bleeding rates when taking other 
drugs that either inhibit CYP 3A4 or compete for P-gp, 
were not found to be increased [28]. Although this study 
with a Taiwanese population may not be generalized to 
Western patients, one should be mindful of amiodarone, 
especially in the perioperative setting, as it is a frequently 
used drug amongst NOAC users.
If co-administration of a NOAC with interacting 
agents cannot be avoided, then a monitoring could be 
beneficial before a surgical intervention [7, 22]. Details 
are summarized in table 3.
Disorders and Interventions with Increased Risk of 
Bleeding
The bleeding risk of a patient undergoing surgery de-
pends on the type of intervention, the patient’s individu-
al characteristics, and the co-medication used. Disorders 
known to increase a patient’s susceptibility to bleeding 
are shown in table 4.
Bleeding Risk of Surgical Interventions
Usually emergency surgery is associated with high or 
increased bleeding risk. Many surgical interventions also 
increase the thromboembolic risk. So, both risks – the one 
for bleeding and the one for thromboembolic events – 
must be balanced [30]. In table 5 bleeding and thrombo-
embolic risks for common surgeries are listed.
Coagulation Tests / Monitoring
The NOACs’ pharmacodynamic and pharmacokinet-
ic profiles are well known, which makes their anticoagu-
lation effects relatively predictable. Therefore, patients 
using NOACs do not require routine coagulation moni-
toring [6, 7, 9, 22, 31].
However, in certain clinical circumstances specific co-
agulation tests are crucial, for example in situations of 
major bleeding, emergency surgery, stroke during treat-
ment, or when the patient has developed renal failure 
[32].
NOAC-specific tests have to be used which measure 
the plasma drug level (μg/ml) or the anti-FXa activity (IU/
Table 2. Pharmacokinetic characteristics of NOACs [6–9, 21]
Dabigatran Apixaban Edoxaban Rivaroxaban
Bioavailability 6.5% 52%1 62% 80–100% (10 mg) 
66–100% (20 mg)
Prodrug yes no no no
Tmax 0.5–2 h 3–4 h 1–2 h 2–4 h 
T1/2 12–14 h 12 h (18–40y) 
15 h (>65y)
10–14 h 5–9 h  
11–13 h (elderly patients)
Trough median (P10-P90), or  
anti-FXa minimum median [21]
2 × 110 mg/day: 
66 (28–155) ng/ml
2 × 150 mg/day:
93 (40–215) ng/ml
2 × 2.5 mg/day: 
0.84 (0.37–1.8) IU/ml
2 × 5 mg/day: 
1.54 (0.61–3.43) IU/ml
1 × 30 mg/day: 
0.35 (0.21–0.57) IU/ml
1 × 60 mg/day: 
0.64 (0.37–1.12) IU/ml
2 × 15 mg/day: 
57 (20–140) ng/ml
1 × 20 mg/day: 
25.6 (5.93–86.9) ng/ml
Peak median (P10-P90), or  
anti-FXa maximum median [21]
2 × 110 mg/day: 
133 (52–275) ng/ml
2 × 150 mg/day: 
184 (74–383) ng/ml
2 × 2.5 mg/day: 
1.3 (0.67–2.4) IU/ml
2 × 5 mg/day: 
2.55 (1.36–4.79) IU/ml
1 × 30 mg/day:
2.1 IU/ml
1 × 60 mg/day: 
3.8 IU/ml
2 × 15 mg/day: 
229 (180–320) ng/ml
1 × 20 mg/day: 
255 (189–419) ng/ml








33% unchanged in urine
Distribution volume 60–70 l 21 l 107 l 50 l
Duration of action [23] 24–36 h 24 h 24 h
Interaction [21] substrate of P-gp metabolized by 
CYP3A4 and substrate 
of P–gp
substrate of P-gp, very 
little metabolization by 
CYP450
metabolized by CYP3A4, 
CYP2J2 and substrate of 
P-gp and BCRP
Interference with food [21] prolongs Cmax  to 2 h none none increases AUC 
2 to 39%
Tmax = Time to maximum plasma concentration; T1/2 = half-life, time to 50% of maximum plasma concentration; FXa = factor Xa; 
P-gp = P-glycoprotein; CYP3A4 = cytochrome P450 3A4; CYP450 = cytochrome P450; CYP2J2 = cytochrome P450 2J2; BRCP = breast 
cancer resistance protein; Cmax = maximum plasma concentration; AUC = area under the curve.
1No effect of meals.
2AUC = Area under curve (plasma concentration-time curve).
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ml). It is important to note, however, that prospective 
endpoint-driven studies assessing the effect of monitor-
ing (± dosing adaptations based on these measurements) 
are lacking; as such, these measurements need to be per-
formed and interpreted by specialists and should not be 
performed on a routine basis even in difficult/high-risk 
patients.
Also, in NOAC patients it may be indicated to carry 
out routine coagulation tests to assess the general coagu-
lation status, especially when bleeding occurred or preop-
eratively.
Table 3. Drug-drug interactions: effect on NOAC plasma-levels, adapted from [29]
Drug Mechanism Dabigatran Apixaban Edoxaban Rivaroxa-
ban
Antiarrhythmic drugs
Amiodarone moderate P-gp competition ↑ – ↑↑ no data ↑↑ (↑)
Digoxin P-gp competition no effect no effect no effect no effect
Diltiazem P-gp competition and weak CYP3A4 
inhibition
no effect ↑↑ no data (↑)
Dronedarone P-gp competition and CYP3A4inhibition ↑↑↑ – ↑↑↑↑ no data ↑↑↑ no data
Quinidine P-gp competition ↑↑ no data ↑↑↑ no data
Verapamil P-gp competition (and weak CYP3A4 
inhibition)
↑ – ↑↑↑↑ no data ↑↑ (↑)
Other cardiovascular drugs




moderate P-gp competition and CYP3A4 
inhibition
↑ no data ↑↑↑ ↑ – ↑↑
Rifampicin P-gp/ BCRP and CYP3A4/CYP2J2 inducers ↓↓ ↓↓ ↓↓
compensatory 




HIV protease inhibitors  
(e.g. ritonavir)
P-gp and BCRP competition or inducer; 
CYP3A4  
inhibition
no data ↑↑↑↑ no data ↑↑↑↑
Fungostatics
Fluconazole moderate CPY3A4 inhibition no data no data no data ↑↑
Itraconazole; ketoconazole; 
posaconazole; voriconazole
potent P-gp and BCRP competition; 
CYP3A4  
inhibition
↑↑↑↑ ↑↑↑↑ ↑↑↑ – ↑↑↑↑ ↑↑↑↑
Immunosuppressives
Cyclosporin; tacrolimus P-gp competition not 
recommended
no data ↑↑↑ no data
Antiphlogistics
Naproxen P-gp competition no data ↑↑ no effect no data
Antacids




P-gp/BCRP and CYP3A4/CYP2J2 inducers ↓↓↓ ↓↓ ↓↓ ↓↓
P-gp = P-glycoprotein; CYP3A4 =cytochrome P450 3A4; BRCP = breast cancer resistance protein; CYP2J2 = cytochrome P450 2J2; GI
↑ up to 30%, ↑↑ up to 60%, ↑↑↑ up to 90%, ↑↑↑↑ > 90%.




- Active gastrointestinal ulcers
- Recent major bleeding (particularly intracranial)
- Recent biopsy, surgery or major trauma
- Bacterial endocarditis
- Liver disease (Child Pugh A, B) 
- Severe renal failure
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Table 6 may help with the interpretation of the test re-
sults, for which it is important to consider the time of last 
intake of the NOAC and the renal function [33].
Prothrombin time (PT): Even though PT is not the 
most effective test available, it is still widely used in prac-
tice for screening [35]. PT is generally not a recommend-
ed test for the direct FXa inhibitors as there is a high vari-
ability and normal values do not exclude clinically rele-
vant levels of the drugs [7, 8, 36, 37]. PT seems to be more 
sensitive towards rivaroxaban than to other FXa inhibi-
tors [6, 33, 38]. PT is not sensitive to dabigatran, thus not 
recommended for its quantification [9].
Activated partial thromboplastin time (aPTT): Due to 
widespread use, around the clock availability, low cost 
and relatively good sensitivity, aPTT may be used for the 
monitoring of dabigatran and as a screening test for the 
risk of bleeding [39]. Again, this test is not useful and not 
recommended for rivaroxaban, apixaban and edoxaban, 
as values show a high variability [6–8, 33, 36].
The aPTT could be useful for an urgent assessment of 
the presence of dabigatran, although normal values might 
still indicate a presence of the drug [33, 40].
Thrombin time (TT): This test is mainly useful to 
screen for the presence or absence of dabigatran, it is not 
useful for the direct FXa inhibitors [6–8, 34, 35]. A nor-
mal TT excludes the presence of dabigatran [41].
Anti-FXa: For rivaroxaban, apixaban and edoxaban 
the most accurate measurement of plasma concentration 
is done with the anti-FXa assay using the specific drug as 
calibrator [6–8, 33, 34, 37]. In some clinics these tests are 
available 24/7 with results obtained in about 20 min, thus 
being a valid method even in urgent situations [22].
Perioperative Management of NOACs
Elective Interventions
The objective of the peri-interventional management 
of patients already under NOAC before surgery is to min-
imize the peri-interventional risk for thromboembolism 
and bleeding.
Except for surgical interventions with very low risk of 
bleeding, NOAC therapy needs to be interrupted [42, 43]. 
Bridging is not recommended, as it has not been found to 
Table 5. Bleeding risk of elective surgeries, adapted from [30]
High risk Medium risk Low risk
Bleeding complications intracranial surgery remaining surgeries transurethral surgery




orbital surgery / posterior 
chamber
ERCP with papillotomy skin biopsies
major tumor surgery biopsies of parenchymatous organs dental hygiene, periodontal surgery, 
dental treatments (except serial teeth 
extractions)
heart surgery bronchoscopy with biopsies
thyroid gland surgery serial teeth extractions, operative 
tooth extraction, oral surgery 




endoprosthesis surgery on upper extremities and all 
remaining interventions on lower  
extremities
minor visceral, urological and 
gynecological surgeries (<30 min) 
with no bed rest
proximal hip fractures 
and plurifragmentary 
fractures
major visceral, urological and 
gynecological surgeries (>30 min) 
orthopedic removal of metal with no 
bed rest and no impairment of joint 
mobility
major pelvic surgery lung, chest wall and mediastinum 
surgeries 
tumor surgery varicose vein surgery
vascular surgery
Table 6. Interpretation of coagulation tests under NOAC, adapted 
from [34]
Test Effect of
dabigatran apixaban edoxaban rivaroxaban
PT/INR – (↑) (↑) 1 ↑
aPTT ↑↑ (↑) (↑) 1 (↑)
TT ↑↑↑ – – –
Anti-FXa – ↑↑ ↑↑ ↑↑
PT = Prothrombin time; INR = internationalized normalized 
ratio; aPTT = activated prothrombin time; TT = thrombin time; 
FXA = factor Xa.
↑Prolonged coagulation test or elevated anti-FXa plasma levels.
1Prolonged, but no known relation with bleeding risk [29]. 
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reduce thromboembolic events, but does increase the 
bleeding risk [42, 44–46]. In cases where interruption is 
not necessary, procedures should be undertaken at trough 
and not at peak levels of NOAC.
Recommendations about pre-interventional discon-
tinuation of NOACs vary. While for interventions with 
low bleeding risk an interruption of NOACs of ≥24 h is 
often considered as sufficient, the proposed period of 
time for interventions with high bleeding risk is between 
2 and 5 days, for dabigatran up to 7 days [20, 29, 47, 48]. 
These recommendations are not supported by clinical 
outcome data, but they rely on pharmacokinetic calcula-
tions using elimination half-lives to predict NOAC levels 
with minimal bleeding risk.
It is usually assumed that an interruption of two to 
three half-lives of the drug is safe for low and intermedi-
ate hemorrhagic risk, and of four to five half-lives for high 
bleeding risk and neuraxial anesthesia. Renal insufficien-
cy therefore may prolong these periods, depending on the 
specific NOAC and its renal elimination.
The recently published CORDIA study examined the 
necessary discontinuation period to reach NOAC levels 
of ≤30 ng/ml, which were assumed to carry minimal 
bleeding risk [43]. Only 5% had NOAC levels of >30 ng/ml 
Table 7. Time of last drug intake, adapted from [29, 51]
Surgery with low risk of 
bleeding
Surgery with high risk of 
bleeding
Dabigatran (dose depending on age and renal function)
CrCl ≥ 50 ml/min (t1/2 = 15 h) 24–36 h before surgery 48–72 h before surgery
CrCl ≥ 30 – <50 ml/min) (t1/2 = 18 h) 48 h before surgery 96 h before surgery
1
Apixaban (2 × 2.5 mg / 2 × 5 mg/day)
Normal or mild insufficiency (CrCl > 50 ml/min) (t1/2 = 7–8 h) 24 h before surgery 48 h before surgery
Moderate insufficiency (CrCl 30–50 ml/min) (t1/2 = 17–18 h) 48 h before surgery 48 h before surgery
Edoxaban (dose depending on age, body weight, renal function)
Normal or mild insufficiency (CrCl > 50 ml/min) (t1/2 = 10–14 h) 24 h before surgery 48 h before surgery
Moderate insufficiency (CrCl 30–50 ml/min) (t1/2 = 10–14 h) 48 h before surgery
2 72 h before surgery2
Rivaroxaban (1 × 15 mg / 1 × 20 mg/day)
Normal or mild insufficiency (CrCl > 50 ml/min) (t1/2 = 8–9 h) 24 h before surgery
3 48 h before surgery
Moderate insufficiency (CrCl 30–50 ml/min) (t1/2 = 9 h) 24 h before surgery 48 h before surgery
Severe insufficiency (CrCl 15–29.9 ml/min) (t1/2 = 9 h) 48 h before surgery 72 h before surgery
CrCl = Creatinine clearance; t1/2 = half-life, 50% of maximum plasma concentration.
1Dabigatran is eliminated mainly by the kidneys (80%); the delay should be prolonged in case of renal insufficiency.
2Edoxaban depends on renal elimination more than rivaroxaban or apixaban. The delay should be increased in case of renal insuf-
ficiency.
3In patients without comorbidities taking 10 mg/d and scheduled for low bleeding risk surgery, the delay can be shortened to 24 h. 
Table 8. Timing of NOAC re-start after surgery [51]
Drug Low bleeding risk surgery High bleeding risk surgery
Dabigatran resume 24 h after surgery, 2 × 150 mg/day 1 resume 48-72 h after surgery, 2 × 150 mg/day 1,2,6
Rivaroxaban resume 24 h after surgery, 1 × 20 mg/day 1 resume 48-72 h after surgery, 1 × 20 mg/day 1,3,6
Apixaban resume 24 h after surgery, 2 × 2.5 mg/day 1 resume 48-72 h after surgery, 2 × 2.5 mg/day 1,4,6
Edoxaban resume 24 h after surgery, 1 × 60 mg/day 1 resume 48-72 h after surgery, 1 × 30 mg/day 1,5,6
1Or the pre-operative, indicated dosage [51].
2For patients at high risk for thromboembolism, consider administration of a reduced dose of dabigatran (e.g. 1× 110–150 mg/day) 
on the evening after surgery and on the following day (first postoperative day) after surgery [59].
3For patients at high risk for thromboembolism, consider administration of a reduced dose of rivaroxaban (e.g. 1 × 10 mg/day) on 
the evening after surgery and on the following day (first postoperative day) after surgery [59].
4For patients at high risk for thromboembolism, consider administration of a reduced dose of apixaban (e.g. 2 × 2.5 mg/day) on the 
evening after surgery and on the following day (first postoperative day) after surgery [51].
5For patients at high risk for thromboembolism, consider administration of a reduced dose of edoxaban (e.g. 1 × 30 mg/day) on the 
evening after surgery and on the following day (first postoperative day) after surgery [51].
6LMWH such as enoxaparin 1 × 40 or 2 × 30 mg/day or mechanical prophylaxis such as intermittent pneumatic compression can be 
considered until therapeutic anticoagulation can be re-introduced [59].
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after 49–2 h, and none >50 ng/ml. These figures were ob-
served in patients with normal and reduced renal func-
tion, making it difficult to derive differentiated recom-
mendations. For shorter discontinuation periods, there 
was a significant interindividual variability of plasma lev-
els [43]. Another publication reported plasma levels of 
rivaroxaban that were higher than expected in patients 
with impaired kidney function (glomerular filtration rate 
< 60 ml/min) and with co-medication amiodarone [49]. 
In unclear situations, it remains reasonable to measure 
NOAC plasma levels.
Based on the limited available data, the NOAC-free 
interval before intervention/surgery for patients with low 
bleeding risk and normal renal function should be ≥24 h 
(for details see table 7). Provided there is no clinical evi-
dence of disturbed hemostasis, the NOAC can be re-start-
ed the day after the intervention (table 8). In patients with 
high bleeding risk and normal renal function the NOAC-
free interval before intervention/surgery is usually ≥48 h 
(for details see table 7), and re-start of the NOAC may 
take place on day 2 or 3 after the intervention, provided 
there are no signs of disturbed hemostasis or surgical con-
traindications [31] (table 8).
The PAUSE trial is expected to provide more data on 
the timing of last intake, plasma levels, and clinical out-
come of NOACs [50].
Emergency Interventions
In emergency situations it is important to know the 
type of NOAC involved, the time of last intake, and the 
patient’s renal function. If NOAC elimination is normal, 
the duration of action is 24 h for FXa antagonists and 
24–36 h for dabigatran [23] (tables 2 and 7). Therefore, 
whenever possible, an intervention/surgery should be de-
layed by 24–48 h after last NOAC intake, in case of renal 
insufficiency even more (table 7) [51]. It may be helpful 
to know the NOAC plasma level, especially when the time 
of last intake is unknown or a relevant plasma level might 
still be present. The latter may be expected particularly in 
patients of advanced age (>75/80 years), low body weight 
(<60 kg), and/or compromised renal function (creatinine 
clearance < 50 ml/min). If it is unclear whether the test 
result represents a value from the ascending or descend-
ing slope of the NOAC plasma level curve, a second test 
after 3–4 h may bring clarification [31].
If an operation cannot be delayed, the further ap-
proach is based on the NOAC plasma level, provided 
there are no other obstacles. For the interpretation of the 
plasma level values, the time of last NOAC intake and re-
nal function are important. Only little data is available on 
the relation between NOAC plasma levels and the bleed-
ing risk in surgical interventions. Levels < 30 ng/ml are 
considered safe for high bleeding risk interventions, 
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whereas levels > 200 ng/ml are associated with a signifi-
cant bleeding risk [52, 53]. 
With plasma levels between 30 and 200 ng/ml, each 
case needs to be assessed individually, depending on the 
bleeding risk [29, 52] (fig. 1).
Spinal and Epidural Anesthesia in Patients Treated 
with NOACs
Guidelines that tackle NOAC management in neur-
axial anesthesia make different recommendations about 
when to stop and when to resume these drugs before and 
after an intervention. The French Group on Perioperative 
Hemostasis (GIHP) for example recommends not to per-
form regional anesthesia techniques as long as a NOAC 
concentration is still prevalent [55]. Other recommenda-
tions suggest different timing schemes of cessation and 
re-initiation of anticoagulant treatment [56–58], or, de-
pending on the type of anesthesia, if discontinuation is 
even necessary at all [56].
No definite evidence is available on this topic. The au-
thors of this paper made a consensus-based conclusion: 
Both neuraxial puncture and the removal of a catheter 
have a comparable bleeding risk. The NOAC-free interval 
before these procedures corresponds with the surgical in-
terventions with high bleeding risk, i.e. at least 5 half-lives 
(table 7).
Deep nerve blocks like psoas compartment or infracla-
vicular blocks are considered to carry the same bleeding 
risk as spinal and epidural anesthesia.
Re-Start of NOACs after Intervention
Same as before when undergoing surgery, the manage-
ment of anticoagulation after an intervention needs to 
balance the bleeding risk of the intervention and the 
thromboembolic risk of the patient. The drug-specific 
guidelines indicate re-initiation of anticoagulation as 
soon as sufficient hemostasis has been accomplished (ta-
ble 8) [6–9].
In patients at high risk of thromboembolism, postop-
erative bridging with low-molecular-weight heparin or 
intravenous unfractionated heparin (according to insti-
tution protocol) can be considered until therapeutic an-
ticoagulation can be re-introduced [59]; a reduced dose 
(e.g. rivaroxaban 1 × 10 mg/day) or mechanical prophy-
laxis such as intermittent pneumatic compression can 
also be considered [59].
Overdoses, Intoxications and Bleeding
Management of Overdoses and Intoxications
Overdoses of NOACs may occur in worsening of renal 
or hepatic function, incidentally or with suicidal inten-
tions. If the elimination of the drug is not significantly 
reduced, the relatively short half-life of NOACs is an ad-
vantage compared to VKAs. In an unclear situation it 
may be helpful to determine plasma levels. Countermea-
sures may be considered, depending on the situation (ta-
ble 9).
Management of Active Bleeding
When bleeding occurs, it is important to first assess the 
event according to severity of blood loss and location. 
Once more, it would be important to know the time of last 
intake and type of NOAC used as well as other factors that 
might influence plasma concentration and hemostasis 
[29]. In most non-life-threatening bleeding events, the 
temporary discontinuation of the NOAC and supportive 
care are sufficient to control the problem [61]. In a study 
with patients using rivaroxaban, even the majority of ma-
jor bleedings (as defined by the International Society on 
Thrombosis and Hemostasis) could be managed with lo-
cal therapy or red blood cell transfusions, with only 37% 
requiring an intervention or surgery [62].
If the clinical situation calls for a more urgent proce-
dure, specific or non-specific reversal agents can be con-
sidered [63].
Currently, only dabigatran can be counteracted with a 
direct (or specific) reversal agent, idarucizumab (ap-
proved 2015 in the US and Europe and 2016 in Switzer-
land). It is highly important to repeat all coagulation tests 
10 min after the administration of idarucizumab, because 
Table 9. Measures to influence the absorption and elimination of NOACs
Dabigatran Apixaban Edoxaban Rivaroxaban
Reduce absorption – activated charcoal until 2–4 
h (up to 6 h [60])
activated charcoal until 
8 h
Increase renal elimination secure effective diuresis sorbitol secure effective diuresis secure effective diuresis
Hemodialysis possible, limited experience1 not effective not effective not effective
1Also risk of bleeding at puncture site [29]. 
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only then other coagulation problems of the patient can 
be clearly diagnosed.
For FXa inhibitors the reversal agent andexanet alfa 
may soon be available (approved May 2018 in the US). 
Should a direct reversal agent not be available, the Swiss 
Society for Anesthesiology and Reanimation recom-
mends the administration of tranexamic acid and poten-
tially desmopressin to attempt a normalization of hemo-
stasis, before using concentrates with pro-coagulant fac-
tors such as prothrombin complex concentrate (PCC) in 
severe bleeding [31, 64]. Activated PCC should only be 
considered in a patient with life-threatening, intractable 
bleeding [29, 63].
Once the bleeding has been stopped, thromboembolic 
prophylaxis needs to be restarted in all patients as soon as 
possible, as patients under oral anticoagulation are par-
ticularly prone to thrombosis and thromboembolic com-
plications (table 10).
Outlook
Currently under investigation are two more reversal 
agents, andexanet alfa (targeting all FXas) and PER977 
(or aripazine or ciraparantag, targeting FXa inhibitors, 
dabigatran and heparins) [61].
Table 10. Management of active bleeding, adapted after [31, 65]
General parameters
Diagnostic Patient history
• Time of last NOAC intake
• Medication interactions
• Potential accumulation (e.g. renal insufficiency)
• Co-medication with platelet aggregation inhibitors
Blood count, PT/INR, aPTT, thrombin time, fibrinogen 
Renal function
Minor bleeding Severe bleeding
Therapeutic
FXa • Symptomatic measures
• Mechanical compression
• Interventional hemostasis
• Tranexamic acid i.v. 10–15 mg/kg, then 
1–5 mg/kg/h. 
• Skip the next dosage. An interruption of 





• Activated charcoal, in case of last intake < 2 h
• Tranexamic acid i.v. 10–15 mg/kg, then 1–5 mg/kg/h. 
CAVE: caution by hematuria
• Desmopressin 0.3 μg/kg i.v.
• PCC
• 3-factor and 4-factor preparations can be used in case of 
severe bleeding
• aPCC, like rFVIIa, only in case of life-threatening 
intractable bleeding
• Antidote andexanet alfa (if available)
• Platelet transfusion when platelet count < 50 G/l
       If the bleeding is controlled:
• Evaluation of prophylactic anticoagulation
• Interruption/cessation of anticoagulation, depending on 
the bleeding complication and the indication for 
anticoagulation
Dabigatran • Mechanical compression
• Interventional hemostasis
• Tranexamic acid 1 g i.v.
• Skip the next dosage. An interruption of 




• Tranexamic acid 1 g i.v.
• Desmopressin 0.3 μg/kg i.v.
• One-time administration of idarucizumab 5 g 
- 2 × 2.5 g / 50 ml over 5–10 min each, or
- 2× bolus injection consecutively
• Platelet transfusion, when platelet count < 50 G/l
       If the bleeding is controlled:
• Evaluation of prophylactic anticoagulation
• Interruption/cessation of anticoagulation, depending on 
the bleeding complication and the indication for 
anticoagulation
PT = Prothrombin time; aPTT = activated partial prothromboplastin time; INR = internalized normalized ratio; i.v. = intravenous; 
PCC = prothrombin complex concentrates;  aPCC = activated prothrombin complex concentrates; rFVIIa = recombinant factor VIIa.
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